Table 3.

SSE risk ratio between groups

Variable	Denosumab (n = 120)	ZA(n = 122)	P - value
Total SSE HR(95%CI)	12.43	19.92	0.002*
	(2.17-17.44)	(3.34–21.35)
SSE HR(95%CI)
within 2 years	6.33	7.27	0.106*
	(1.36-12.38)	(1.54–19.63)
after 2 years	36.26	83.52	0.001*
	(3.31-161.15)	(4.29–92.60)

^* Statistically significant values. SSEs: symptomatic skeletal events; ZA: zoledronic acid; HR: hazard ratio; CI: confidence interval